Dr. Laura Mauri is Professor of Medicine at Harvard Medical School and Physician at Brigham and Women’s Hospital where she is a practicing interventional cardiologist. Dr. Mauri’s research regarding new medical device effectiveness and late adverse events have formed a reference point for the clinical evaluation of new medical technology, providing a greater understanding of the interactions between medical devices, general clinical practice, and concurrent pharmaceutical therapy. Particular areas of research interest have been the statistical validation of robust surrogate endpoints, selection of observational vs randomized trial methods to compare treatment strategies, and identifying methods to improve trial design and execution in order to facilitate innovation across clinical specialties. She has lead a large international randomized trial of patients undergoing percutaneous coronary intervention, a broadly inclusive, streamlined trial to investigate the impact of antiplatelet therapy duration on long term mortality and cardiac morbidity, partnering with the US Food and Drug Administration and 8 pharmaceutical and device manufacturers. Dr. Mauri is Chief Scientific Adviser of Harvard Clinical Research Institute, an academic research organization with ~200 employees specialized in the full execution of clinical trials. In this regard, she has supervised the design, leadership, and analysis of clinical trials data across nearly 100 medical device trials.